Concordance of immunological events between intrarectal and intravenous SHIVAD8-EO infection when assessed by Fiebig-equivalent staging.


Journal

The Journal of clinical investigation
ISSN: 1558-8238
Titre abrégé: J Clin Invest
Pays: United States
ID NLM: 7802877

Informations de publication

Date de publication:
01 09 2021
Historique:
received: 21 05 2021
accepted: 22 07 2021
entrez: 8 10 2021
pubmed: 9 10 2021
medline: 16 11 2021
Statut: ppublish

Résumé

Primary HIV-1 infection can be classified into six Fiebig stages based on virological and serological laboratory testing, whereas simian-HIV (SHIV) infection in nonhuman primates (NHPs) is defined in time post-infection, making it difficult to extrapolate NHP experiments to the clinics. We identified and extensively characterized the Fiebig-equivalent stages in NHPs challenged intrarectally or intravenously with SHIVAD8-EO. During the first month post-challenge, intrarectally challenged monkeys were up to 1 week delayed in progression through stages. However, regardless of the challenge route, stages I-II predominated before, and stages V-VI predominated after, peak viremia. Decrease in lymph node (LN) CD4+ T cell frequency and rise in CD8+ T cells occurred at stage V. LN virus-specific CD8+ T cell responses, dominated by degranulation and TNF, were first detected at stage V and increased at stage VI. A similar late elevation in follicular CXCR5+ CD8+ T cells occurred, consistent with higher plasma CXCL13 levels at these stages. LN SHIVAD8-EO RNA+ cells were present at stage II, but appeared to decline at stage VI when virions accumulated in follicles. Fiebig-equivalent staging of SHIVAD8-EO infection revealed concordance of immunological events between intrarectal and intravenous infection despite different infection progressions, and can inform comparisons of NHP studies with clinical data.

Identifiants

pubmed: 34623326
pii: 151632
doi: 10.1172/JCI151632
pmc: PMC8409578
doi:
pii:

Types de publication

Comparative Study Journal Article Research Support, N.I.H., Extramural Research Support, N.I.H., Intramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : NCI NIH HHS
ID : 75N91019D00024
Pays : United States
Organisme : CCR NIH HHS
ID : HHSN261200800001C
Pays : United States
Organisme : NCI NIH HHS
ID : HHSN261200800001E
Pays : United States

Références

J Int AIDS Soc. 2020 Jan;23(1):e25444
pubmed: 31953919
Nat Commun. 2020 Jan 7;11(1):70
pubmed: 31911610
J Virus Erad. 2016;2:43-48
pubmed: 26889497
Sci Transl Med. 2017 Feb 15;9(377):
pubmed: 28202771
J Acquir Immune Defic Syndr. 2013 Jul;63 Suppl 2:S187-99
pubmed: 23764635
Nature. 2018 Nov;563(7731):360-364
pubmed: 30283138
Nat Med. 2018 Jul;24(7):923-926
pubmed: 29892063
J Virol. 1999 Feb;73(2):1573-9
pubmed: 9882363
Sci Adv. 2019 May 29;5(5):eaav7116
pubmed: 31149634
Am J Pathol. 1993 Jun;142(6):1750-8
pubmed: 8506945
Am J Pathol. 1988 Dec;133(3):516-24
pubmed: 3059804
Histopathology. 1997 Jan;30(1):31-40
pubmed: 9023555
Nat Med. 2016 Apr;22(4):362-8
pubmed: 26998834
Front Immunol. 2014 Mar 19;5:85
pubmed: 24678309
J Virol. 2005 Jul;79(14):9217-27
pubmed: 15994816
Blood. 2001 May 1;97(9):2695-701
pubmed: 11313260
PLoS Pathog. 2014 Sep 25;10(9):e1004406
pubmed: 25254512
PLoS Pathog. 2016 Jul 27;12(7):e1005777
pubmed: 27463374
PLoS One. 2012;7(3):e33948
pubmed: 22479485
Curr Top Microbiol Immunol. 2018;417:69-109
pubmed: 29026923
J Immunol. 2014 Nov 1;193(9):4527-36
pubmed: 25246494
Sci Transl Med. 2020 Mar 4;12(533):
pubmed: 32132218
Nature. 2017 Mar 23;543(7646):559-563
pubmed: 28289286
AIDS. 2003 Sep 5;17(13):1871-9
pubmed: 12960819
Proc Natl Acad Sci U S A. 2012 Nov 27;109(48):19769-74
pubmed: 23129652
Pathog Immun. 2016 Spring;1(1):68-106
pubmed: 27430032
Blood. 2012 Nov 15;120(20):4172-81
pubmed: 22990012
JAMA. 1998 Jul 1;280(1):42-8
pubmed: 9660362
J Exp Med. 2000 Dec 4;192(11):1553-62
pubmed: 11104798
Nature. 2013 Nov 14;503(7475):224-8
pubmed: 24172905
J Immunol. 2016 Sep 1;197(5):1832-42
pubmed: 27481845
Lancet HIV. 2018 Jan;5(1):e35-e44
pubmed: 28978417
J Clin Invest. 2012 Sep;122(9):3281-94
pubmed: 22922258
J Exp Med. 2013 Jan 14;210(1):143-56
pubmed: 23254284
J Virol. 2016 Oct 28;90(22):10339-10350
pubmed: 27630228
Nature. 2000 Jul 20;406(6793):309-14
pubmed: 10917533
Nat Med. 2017 Nov;23(11):1271-1276
pubmed: 28967921
Nat Med. 2017 Nov;23(11):1277-1286
pubmed: 29035370
J Int AIDS Soc. 2017 Jun 26;20(1):21652
pubmed: 28691436
Immunity. 2007 Aug;27(2):190-202
pubmed: 17723214
J Exp Med. 2000 Dec 4;192(11):1545-52
pubmed: 11104797
Nature. 2013 Nov 14;503(7475):277-80
pubmed: 24172896
J Interferon Cytokine Res. 2005 Nov;25(11):702-6
pubmed: 16318584
EBioMedicine. 2016 Sep;11:68-72
pubmed: 27460436
BMC Infect Dis. 2011 Mar 01;11:56
pubmed: 21362195
J Virol. 2017 Jul 27;91(16):
pubmed: 28539448
J Virol. 2003 Nov;77(22):11896-909
pubmed: 14581526
J Virol. 2009 Apr;83(8):3719-33
pubmed: 19176632
J Exp Med. 2021 Jan 4;218(1):
pubmed: 32966579
Sci Transl Med. 2017 Jan 18;9(373):
pubmed: 28100833
Proc Natl Acad Sci U S A. 2016 Jun 14;113(24):E3413-22
pubmed: 27247400
Nature. 2009 Apr 23;458(7241):1034-8
pubmed: 19262509
AIDS. 1991 Sep;5(9):1071-9
pubmed: 1930770
J Exp Med. 2014 Sep 22;211(10):2061-74
pubmed: 25155019
AIDS. 2016 Jan;30(2):193-201
pubmed: 26558730
J Virol. 2015 Nov 18;90(3):1321-32
pubmed: 26581981
Curr HIV/AIDS Rep. 2012 Jun;9(2):101-10
pubmed: 22415472
J Clin Invest. 2018 May 1;128(5):2089-2103
pubmed: 29664020
J Clin Invest. 2012 Sep;122(9):3271-80
pubmed: 22922259
J Virol. 2018 May 14;92(11):
pubmed: 29563297
Nat Med. 2015 Feb;21(2):132-9
pubmed: 25599132
J Theor Biol. 2009 Nov 21;261(2):341-60
pubmed: 19660475

Auteurs

Joana Dias (J)

Immunology Laboratory, Vaccine Research Center.

Giulia Fabozzi (G)

Tissue Analysis Core, Vaccine Research Center.

Kylie March (K)

Tissue Analysis Core, Vaccine Research Center.

Mangaiarkarasi Asokan (M)

Virology Laboratory, Vaccine Research Center.

Cassandra G Almasri (CG)

Virology Laboratory, Vaccine Research Center.

Jonathan Fintzi (J)

Biostatistics Research Branch.

Wanwisa Promsote (W)

Immunology Laboratory, Vaccine Research Center.

Yoshiaki Nishimura (Y)

Laboratory of Molecular Biology, and.

John-Paul Todd (JP)

Translational Research Program, Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA.

Jeffrey D Lifson (JD)

AIDS and Cancer Virus Program, Leidos Biomedical Research Inc., Frederick National Laboratory for Cancer Research, Frederick, Maryland, USA.

Malcolm A Martin (MA)

Laboratory of Molecular Biology, and.

Lucio Gama (L)

Immunology Laboratory, Vaccine Research Center.

Constantinos Petrovas (C)

Tissue Analysis Core, Vaccine Research Center.

Amarendra Pegu (A)

Virology Laboratory, Vaccine Research Center.

John R Mascola (JR)

Virology Laboratory, Vaccine Research Center.

Richard A Koup (RA)

Immunology Laboratory, Vaccine Research Center.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH